Biodistribution and radiation dosimetry of intraperitoneally administered (124)I-omburtamab in patients with desmoplastic small round cell tumors Journal Article

   


Authors: Grkovski, M.; Modak, S.; Zanzonico, P. B.; Carrasquillo, J. A.; Larson, S. M.; Humm, J. L.; Pandit-Taskar, N.
Article Title: Biodistribution and radiation dosimetry of intraperitoneally administered (124)I-omburtamab in patients with desmoplastic small round cell tumors
Abstract: The aim of this study was to assess the pharmacokinetics, biodistribution, and radiation dosimetry of 124I-omburtamab administered intraperitoneally in patients with desmoplastic small round cell tumor (DSRCT). Methods: Eligible patients diagnosed with DSRCT with peritoneal involvement were enrolled in a phase I trial of intraperitoneal radioimmunotherapy with 131I-omburtamab (NCT01099644). After thyroid blockade and prior to radioimmunotherapy, patients received ~74 MBq 124Iomburtamab intraperitoneally. Five serial PET/CT scans were performed up to 144 h postinjection. Multiple blood samples were obtained up to 120 h post-injection. Organ absorbed doses were calculated with OLINDA/EXM. Results: Thirty-one patients were studied. Blood pharmacokinetics exhibited a biphasic pattern consisting of an initial rising phase with a median half-time (±standard deviation) of 23±15 h and a subsequent falling phase with a median half-time of 56±34 h. Peritoneal distribution was heterogenous and diffuse in most patients. Self-dose to the peritoneal cavity was 0.58 ± 0.19 mGy/MBq. Systemic distribution and activity in major organs were low. The median absorbed doses were 0.72±0.23 mGy/MBq for liver, 0.48±0.17 mGy/MBq for spleen, and 0.57±0.12 mGy/MBq for kidneys. The mean effective dose was 0.31±0.10 mSv/MBq. Whole-body and peritoneal cavity biological half-times were 45±9 h and 24±5 h, respectively. Conclusion: PET/CT imaging with intraperitoneally administered 124I-omburtamab enables assessment of intraperitoneal distribution and estimation of absorbed dose to peritoneal space and normal organs prior to therapy. © 2022 Society of Nuclear Medicine Inc.. All rights reserved.
Keywords: adolescent; adult; child; clinical article; cancer patient; positron emission tomography; cancer diagnosis; spleen; diagnostic imaging; monoclonal antibody; antibodies, monoclonal; radioactive iodine; drug distribution; tissue distribution; iodine radioisotopes; blood sampling; dosimetry; positron-emission tomography; iodine 124; drug absorption; radiometry; phase 1 clinical trial; drug half life; radioimmunotherapy; liver parenchyma; kidney parenchyma; desmoplastic small round cell tumor; intraperitoneal; peritoneal cavity; iodine-124; dsrct; humans; human; male; female; article; positron emission tomography-computed tomography; positron emission tomography computed tomography; effective dose (radiation); omburtamab
Journal Title: Journal of Nuclear Medicine
Volume: 63
Issue: 7
ISSN: 0161-5505
Publisher: Society of Nuclear Medicine  
Date Published: 2022-07-01
Start Page: 1094
End Page: 1100
Language: English
DOI: 10.2967/jnumed.121.262793
PUBMED: 34857661
PROVIDER: scopus
PMCID: PMC9258578
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85133238290&doi=10.2967%2fjnumed.121.262793&partnerID=40&md5=b9c909ebfa3c7cf3efac72754915f28c
Notes: Article -- Export Date: 1 August 2022 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Shakeel Modak
    249 Modak
  2. Neeta Pandit-Taskar
    342 Pandit-Taskar
  3. John Laurence Humm
    433 Humm
  4. Pat B Zanzonico
    355 Zanzonico
  5. Jorge Carrasquillo
    140 Carrasquillo
  6. Steven M Larson
    959 Larson
  7. Milan Grkovski
    64 Grkovski
Related MSK Work